Andres Gomez

Bristol-Myers Squibb
Vice President, Head of Epidemiology, Safety Science, and Analytics
Dr. Gomez joined at Bristol Myers Squibb Company as an Associate Director of Pharmacoepidemiology in the Global Pharmacovigilance and Epidemiology department in 2003. He currently heads the epidemiology, safety science and analytics groups which is accountable for the real world research and signal management necessary to support the interpretation of safety signals of compounds in the BMS. His current position has given him an opportunity to work in the development of risk management plans and participate in negotiations with the FDA and EMA for such drugs as muraglitazar, Avalide, Onglyza, Nulojix and Orencia.

My Speakers Sessions

Tuesday, June 25